GLP-1 receptor agonists and cardiovascular-metabolic benefits
The Lancet
2017
Study summary
Review of GLP-1 receptor agonists across glycemia, weight, and cardiovascular outcomes.
Peptides studied
Goals studied
Stack studied
Metabolic Stack
Key findings
GLP-1 therapies showed broad metabolic and cardiovascular benefits across trials.
Study details
Study type
review article
Journal
The Lancet
DOI / PubMed
10.1016/S0140-6736(17)31205-2
Year
2017
Explore peptide profiles
Discover compounds, understand their mechanisms, and explore the research behind each peptide.